10:33 AM
 | 
Nov 07, 2018
 |  BC Extra  |  Financial News

Mirum launches with liver disease candidates from Shire

Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched with a $120 million series A round and a license from Shire plc (LSE:SHP; NASDAQ:SHPG) to a pair of candidates to treat liver diseases. The start-up intends to start Phase III testing next year of one compound, maralixibat (formerly SHP-625), to treat Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC).

New Enterprise Associates led the round. Also participating were Deerfield Management, Frazier Healthcare Partners, Novo Holdings A/S (Hellerup, Denmark), Pappas Capital, RiverVest Venture Partners and Rock Springs Capital.

Both of Mirum's lead candidates...

Read the full 426 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD